Desmodium

Desmodium: A Comprehensive Reference

1. Identity, Botanical Classification, and Natural Sources

Desmodium is a large genus of flowering plants belonging to the family Fabaceae (Leguminosae), subfamily Faboideae (also referred to as Papilionaceae). The genus Desmodium is a large member of the Papilionaceae (Fabaceae) family and contains about 350 plant species used for both feeding stuffs and herbal medicines, of which only about 30 species have been phytochemically or pharmacologically investigated. As a dietary supplement and medicinal ingredient, the term "Desmodium" most commonly refers to two specific species: Desmodium adscendens (Sw.) DC. and Desmodium gangeticum (L.) DC., both of which have distinct geographical, ethnobotanical, and phytochemical profiles.

1.1 Desmodium adscendens (Sw.) DC.

Desmodium adscendens (Sw.) DC., abbreviated "DA", is a perennial medicinal plant from the Fabaceae family found in tropical and subtropical areas of the world. It is a climbing biennial herbaceous plant common in moist, shaded places in the tropical and subtropical regions of the Americas, Africa, and India. However, it is native to West Africa, where it climbs and winds around cacao trees. The Latin name desmodium derives from the Greek desmos (bond) and adscendens (ascent), a reference to its climbing growth habit.

About fifty centimetres tall, its leaves resemble those of a clover, and its flowers — small and mauve — develop after flowering into small bean-like pods covered with hairs that cling to animals or walkers' trousers to be dispersed in nature. The plant is also known by regional common names; in Mato Grosso, Brazil, the plant is known as "amores do campo" or "carrapichinho," and in São Paulo and Rio Grande do Sul as "pega-pega."

This herbaceous plant occurs in Africa and South America, where a decoction from leaves and stems is used in traditional medicine for various indications, including the management of asthma and for its hepatoprotective activity. The leaves are the parts primarily used medicinally.

1.2 Desmodium gangeticum (L.) DC.

Desmodium gangeticum, commonly known as "Salpan" or "Salpani" in Hindi and "Shalparni" in Sanskrit, is used in Ayurveda, Siddha, and Unani systems of medicine either as a single drug or in combination with other drugs. Desmodium gangeticum (L.) DC., commonly known as Shalparni in Ayurveda, has been used for treating various diseases, and the plant is one of ten ingredients of the classical Ayurvedic formulation known as Dasamula.

1.3 Common Forms and Preparations

Both species are available in a range of preparations. The most traditionally significant are aqueous decoctions and ethanolic extracts of the aerial parts (leaves and stems). Decoctions of root and leaf, root powder, and leaf juice of D. gangeticum are used as tonics, febrifuge, digestive, antiemetic, astringent, anti-asthmatic, antidiarrhoeal, and anti-inflammatory agents in traditional medicinal practices. Modern commercial forms include standardised dry extracts in capsule or tablet form, herbal teas, and hydroalcoholic liquid extracts. A patent has been taken on the use of Desmodium, especially D. adscendens, in the treatment of viral or chemically-induced hepatitis. In Europe, the plant has been introduced as a liver-support supplement and was notably championed in France. It was introduced to France in the late 1960s by Dr. Pierre Tubéry.

2. Traditional and Historical Use

2.1 West and Sub-Saharan Africa

Desmodium adscendens is widely used for the treatment of asthma in Ghana, Africa. More than 100 traditional medicinal uses have been reported in 43 countries, highlighting use in inflammatory, gastrointestinal and infectious processes, muscular pain, rheumatic, renal, and hepatic affections. Desmodium is very popular in African traditional medicine for treating hepatitis. In Ghana specifically, herbalists have long administered the plant orally, most commonly as a water-based decoction or maceration of the leaves and stems, for respiratory complaints including asthma and bronchitis.

The plant has been found to be very useful in the treatment of constipation and other gastrointestinal ailments, bronchial asthma, inflammations, and coughs and colds. Leaf extract of the plant is also applied externally for the treatment of snake bites and wounds in general.

2.2 South America and the Caribbean

The plant is noted as analgesic, antiasthmatic, anti-inflammatory, antispasmodic, antitussive, bronchodilator, digestive, galactagogue, laxative, nervine, vermifuge, and vulnerary in traditional South American usage. An application of pounded leaves and lime juice is applied to wounds. The entire plant is also soaked in rum for 24 hours, and then one quarter cup is taken three times daily for seven to ten days as a treatment for backaches.

2.3 India — Ayurvedic, Siddha, and Unani Traditions

D. gangeticum (Fabaceae, subfamily Faboideae) has been used extensively as a traditional medicine in India over a long period of time and its uses have been well documented. It is described as a bitter tonic, febrifuge, digestive, anticatarrhal, and antiemetic, used in inflammatory conditions of the chest and in various other inflammatory conditions due to "vata" disorder. The roots have been used as an expectorant and in snakebite and scorpion sting. It is an ingredient of Ayurvedic preparations like "Dashmoolarishta" and "Dashmoolakwaath," recommended for post-natal care to avoid secondary complications.

2.4 Chinese Traditional Medicine

In China, the use of Desmodium spp. for ethnomedicinal purposes dates back as far as 3000 years ago. They were mainly used to treat fever, block pain, restore blood circulation, counteract toxins, remove cough, and relieve dyspnea. Plants of the genus Desmodium, such as D. styracifolium and D. gyrans, have a long history of medical use in Traditional Chinese Medicine to treat various ailments including rheumatism, pyrexia, dysentery, wounds, cough, malaria, hepatitis, and hemoptysis.

2.5 Breadth of Traditional Applications Across Cultures

This herb has been traditionally used in numerous countries all over the world for its pharmacological and biological properties — including for the treatment of diarrhoea, fever, epilepsy, asthma, leishmaniasis, gastroduodenal ulcer, diabetes, and hepatic diseases. Currently in Chinese and Indian medicines, Desmodium species are used to treat fever, rheumatism, hemoptysis, abscess, common cold, wounds, icteric hepatitis, pharyngitis, infantile malnutrition, dysentery, urinary diseases, parotitis, cholecystitis, malaria, and epidemic encephalitis.

3. Key Constituents and Active Compounds

3.1 Phytochemistry of Desmodium adscendens

D. adscendens is a plant of the Fabaceae family especially rich in flavonoids but also in alkaloids, terpenoids, steroids, phenols, phenylpropanoids, glycosides, and volatiles. Detailed phytochemical analyses have identified the following compound classes and individual molecules:

• Triterpenoid Saponins: Phytochemical research on D. adscendens has led to the isolation of triterpenoid saponins, phenylethylamines, and indole-3-alkyl amines. The most studied individual saponins are soyasaponin I, soyasaponin III, and dehydrosoyasaponin I (DHS-I).
• Flavonoids: A phytochemical study using planar chromatography revealed the presence of flavonoids such as vitexin and isovitexin, and soyasaponins such as soyasaponin I. Flavonoids including rutin, vitexin, and isovitexin have been isolated from D. adscendens. HPLC analyses revealed that the main phenolic compound identified in the methanol–water extract was quercetin dihydrate (2.11 mg/mL).
• Cyclitols: D-pinitol was characterised as a potentially active compound with hypoglycemic and antiatherogenic activity in vitro and antihyperglycemic, hepatoprotective, and anti-inflammatory effects in vivo.
• Amines: The antiasthmatic indication has been related to the presence of triterpenoid saponins, tetrahydroquinolines, β-phenylethylamines, and indol-3-alkylamines in the plant, and their influence on arachidonic acid metabolism. An indole alkaloid, salsoline, has also been identified.
• Fatty Acids: Among the identified fatty acids in the plant, oleic acid (38.7%), linoleic acid (35.4%), palmitic acid (11.2%), behenic acid (8.0%), and stearic acid (4.5%) were the main constituents.
• General phytochemical profile: D. adscendens has a high content of flavonoids, polyphenols, and reducing sugars. Alkaloids, glycosides, saponins, and tannins were also present, but not in high concentration.

In total, 212 compounds have been isolated from 15 Desmodium species and characterised mainly as flavonoids and alkaloids, followed by terpenoids, steroids, phenols, phenylpropanoids, glycosides, and a number of volatile oils.

3.2 Phytochemistry of Desmodium gangeticum

Phytochemical research on D. gangeticum has led to the isolation of alkaloids, pterocarpans, phospholipids, sterols, flavones, and flavonoid glycosides.

• Pterocarpans: The active constituents desmodin, hordenine, and gangetin are largely responsible for its broad spectrum of therapeutic potential. Desmodin belongs to the class of pterocarpans and is reported to have antifungal and antibacterial activities. Gangetin, which also belongs to the pterocarpans, is reported to have anti-inflammatory and analgesic effects.
• Alkaloids: The plant tissues contain a number of prominent phytochemicals including hordenine, desmodin, palmitic acid, candicine, hypaphorine, gangetin, and desmocarpin, among numerous others.
• Drug-likeness of pterocarpans: ADME-PK properties of pterocarpans such as gangetin, gangetinin, desmocarpin, and desmodin were found to pass the Lipinski, Ghose, Veber, and Egan rules, supporting drug-likeliness.
• General profile: The phytochemical profiling showed that the ethanolic extract of the aerial part contained glycoside, amino acid, phenols, alkaloids, flavonoids, and coumarins, while the ethanolic root extract revealed the presence of glycoside, amino acid, phenols, alkaloids, flavonoids, coumarins, and triterpenoids.

4. Established Mechanisms of Action

4.1 Activation of Calcium-Dependent Potassium (Maxi-K) Channels — Bronchodilatory / Smooth Muscle Relaxant Mechanism

The triterpenoid saponins soyasaponin I, soyasaponin III, and especially dehydrosoyasaponin I were identified as the constituents responsible for the activation of calcium-dependent potassium channels, a mechanism which is expected to relax airway smooth muscle cells. Large-conductance calcium-dependent potassium (maxi-K) channels play an important role in regulating the tone of airway smooth muscle and the release of bronchoconstrictive substances from nerves in the lung. Crude extracts of D. adscendens, a medicinal herb used in Ghana as a treatment for asthma, inhibit binding of monoiodatyrosine charybdotoxin to receptor sites in bovine tracheal smooth muscle membranes associated with maxi-K channels. This natural product was described as the first example of a high-affinity activator of calcium-dependent potassium channels and the most potent known potassium channel opener at the time of its discovery.

4.2 Inhibition of Arachidonic Acid Cascade — Anti-inflammatory and Antiasthmatic Mechanism

Studies show that the aqueous extract of Desmodium contains several types of active substances that act at different levels in the arachidonic acid cascade, thereby effectively and synergistically inhibiting the release of bronchoconstrictive compounds and antigens, which confirms the antiasthmatic and antiallergic activity of this plant. A flash chromatography fraction of D. adscendens leaves inhibited both the early and late phases of antigen-induced contractions of tracheal spirals and lung parenchymal strips dose-dependently. The results suggest that this fraction may inhibit the release of free arachidonic acid.

4.3 Hepatoprotective Mechanisms

The hepatoprotective effect of Desmodium against hepatotoxic compounds appears to be related to its content of triterpenoid saponins. According to an in vitro study, soyasaponins I and III, dehydrosoyasagenin I, and soyasapogenol E protect liver cells from damage induced by hepatotoxic substances such as carbon tetrachloride, with normalisation of hepatic transaminase levels, mainly GOT (ASAT). D-pinitol, a cyclitol present in the plant, represents an additional hepatoprotective mechanism. D-pinitol has hypoglycemic and antiatherogenic activity in vitro and antihyperglycemic, hepatoprotective, and anti-inflammatory effects in vivo.

4.4 Antioxidant and Cytoprotective Mechanisms

In a study evaluating a hydroalcoholic extract of D. adscendens on HepG2 liver and LLC-PK1 kidney cells, a viability test, cytotoxicity assay, and study of cell morphology revealed that pretreatment with 1 mg/mL or 10 mg/mL DA did not alter viability or LDH release in either cell type. The high content of flavonoids and polyphenols, including rutin, vitexin, and quercetin, is thought to contribute to the antioxidant and cytoprotective actions observed in laboratory models.

5. Scientific Evidence by Area of Use

5.1 Respiratory: Asthma, Bronchospasm, and Anti-anaphylactic Effects

Evidence level: Primarily preclinical (in vitro and animal models); limited human data.

The antiasthmatic properties of D. adscendens have been the most extensively studied area at a preclinical level. Liquid chromatography was used to fractionate the crude aqueous extract of D. adscendens, a plant shown to be anti-anaphylactic and used locally for the treatment of asthma. Inhibition of electrically-induced contraction of ileal pieces was used to follow the activity of the fractions. Several chromatographically distinct active fractions were isolated and found to inhibit ovalbumin-, histamine-, and carbachol-induced contraction of guinea pig airway tissue in vitro.

In vivo studies using the guinea-pig model showed that both aqueous and ethanolic extracts of D. adscendens, when taken orally, reduce anaphylactic contractions, interfere with histamine-induced contractions, and reduce the amount of smooth muscle-stimulating substances released from lung tissue. D. adscendens was also found to be effective in relaxing smooth muscle contractions.

While this preclinical body of work is mechanistically coherent and pharmacologically robust, no large-scale, randomised controlled trials in human asthma patients have been identified in the peer-reviewed literature. The existing evidence base is therefore insufficient to draw definitive clinical conclusions about efficacy in human asthma, although the mechanistic rationale — activation of maxi-K channels and suppression of the arachidonic acid cascade — is well characterised at the preclinical level.

5.2 Hepatoprotection and Liver Disease

Evidence level: In vitro and animal data are strong; limited preliminary human data.

Hepatoprotection is the most clinically evaluated area for D. adscendens. The antihepatotoxic properties of an aqueous decoction of D. adscendens have been evaluated formally. This plant occurs in Africa and South America, where a decoction from leaves and stems is used in traditional medicine, including for its hepatoprotective activity.

In preclinical work, in an experiment evaluating the protective effect against acute D-galactosamine-induced liver damage in rats, a significant decrease of AST and ALT was observed for the D. adscendens decoction at a dose equivalent to 5 mg/kg/day. This anti-hepatotoxic activity was confirmed in vivo with a decoction of Desmodium quantified as D-pinitol.

A patent covering the use of D. adscendens in viral or chemically-induced hepatitis was filed (Tubéry and Tubéry, 1989). The effect of Desmodium was further evaluated in a clinical study carried out on 50 patients with viral hepatitis who received treatment with Desmodium (3 times per day) for 45 days. However, detailed peer-reviewed publication of this trial's full methodology and results has not been identified in the indexed literature, limiting the strength of the clinical interpretation.

Head and neck cancer patients require integrative support during chemotherapy to preserve hepatic, intestinal, and renal functions. Desmodium adscendens, a plant of African origin with anti-allergic, antioxidant, and hepatoprotective properties, has active constituents to preserve liver function, mainly contained in the trunk and leaves, such as triterpenic saponosides, soy saponins, and indole alkaloids.

5.3 Oncology Support (Feasibility Study)

Evidence level: Very preliminary; single-arm uncontrolled feasibility study only.

In a single-arm study, researchers investigated the efficacy of a combination therapy based on Desmovit® (which contains Desmodium and Lithothamnium calcareum) combined with chemotherapy in patients with head and neck cancer. Twelve patients with a histological or cytological diagnosis of stage IV head and neck cancer were enrolled. Twelve patients received an intravenous infusion of paclitaxel or methotrexate and a medical device containing 300 mg of DA leaves and 50 mg of L. calcareum. It was found that chemotherapy combined with Desmodium and Lithothamnium improved pain and fatigue in head and neck cancer patients, although it was not confirmed whether this was due to Desmovit and Lithothamnium or to chemotherapy alone. This study is extremely limited in size and design; no conclusions about efficacy of Desmodium can be drawn from it in isolation.

5.4 Anti-inflammatory and Analgesic Activity

Evidence level: In vitro and animal data; no robust clinical trials identified.

Crude extracts, fractions, and isolated components of D. adscendens showed in vitro and in vivo pharmacological activities including anti-inflammatory activity. For D. gangeticum, the pterocarpan gangetin has been reported to have anti-inflammatory and analgesic effects in preclinical models. Various studies have demonstrated that D. gangeticum exhibits a range of therapeutic effects including anti-inflammatory, analgesic, anti-cancer, antipyretic, antidepressant, and antioxidant properties, attributed to the presence of secondary biochemical compounds such as alkaloids, pterocarpans, flavonoids, phenols, saponins, phospholipids, glycolipids, sterols, and flavone glycosides.

5.5 Antidiabetic and Metabolic Activity

Evidence level: Animal and in vitro data only; no human clinical trials identified.

Desmodium plant extracts, as well as active principles, have been experimentally studied for their anti-inflammatory, cytotoxic, antidiabetic, antinephrolithic, antibacterial, and nootropic activities in vitro or in vivo. The cyclitol D-pinitol, which has been identified in D. adscendens, is associated with antihyperglycemic and hepatoprotective effects in animal studies, though direct human evidence for Desmodium specifically in managing diabetes is lacking.

5.6 Antileishmanial and Immunomodulatory Activity

Evidence level: Preclinical (in vitro and animal); no clinical trials identified.

D. gangeticum possesses the ability to scavenge free radicals generated during ischaemia and ischaemia-reperfusion, thereby preserving mitochondrial respiratory enzymes, leading to cardioprotection, and has potential prophylactic and therapeutic efficacy against Leishmania infection. In India, D. adscendens has been reported to possess antileishmanial, antioxidant, immunomodulatory, antiulcer, cardioprotective, antidiabetic, anti-amnesia, antiviral, and hepatoprotective activities. All of these remain at the preclinical stage of investigation.

5.7 Gastrointestinal / Antiulcer Activity

Evidence level: Preclinical; no clinical trials identified.

More than 100 traditional medicinal uses have been reported in 43 countries, highlighting use in gastrointestinal processes. Among the 45 biological activities experimentally evaluated, antioxidant, antimicrobial, anti-inflammatory, hepatoprotective, and antinociceptive were the most reported. Gastrointestinal uses — including antiulcer activity — have been observed in laboratory and animal models but have not been validated in controlled human clinical trials.

5.8 Central Nervous System Effects (Anti-amnesic / Nootropic)

Evidence level: Animal/rodent models only.

Antiamnesic activity has been observed in in vitro and in vivo pharmacological assessments of D. adscendens crude extracts and isolated components. These effects are documented in rodent models and have not been translated into human clinical evidence.

6. Body Systems and Health Areas Associated with Desmodium

• Respiratory system: Antiasthmatic, bronchodilatory, anti-anaphylactic, antitussive activity — primarily D. adscendens
• Hepatic system: Hepatoprotection, reduction of transaminase elevation, antihepatotoxic activity — both species, particularly D. adscendens
• Immune system: Immunomodulatory, antileishmanial, antiviral activity
• Metabolic / endocrine system: Antidiabetic, antihyperglycemic, antiatherogenic activity (primarily linked to D-pinitol)
• Cardiovascular system: Cardioprotective activity via free-radical scavenging — primarily D. gangeticum
• Gastrointestinal system: Antiulcer, digestive, antiemetic, antidiarrhoeal, constipation management
• Musculoskeletal system: Analgesic in back pain, joint pain, muscle cramp, and rheumatic conditions
• Central nervous system: Anti-amnesic (nootropic) in preclinical models; anticonvulsant activity noted in animal studies
• Integumentary system: Wound healing, treatment of infections

Among the 45 biological activities experimentally evaluated across the Desmodium genus, antioxidant, antimicrobial, anti-inflammatory, hepatoprotective, and antinociceptive were the most reported.

7. Dosage Forms and Dosages Reported in Studies

The following dosages are drawn only from identified research; they do not represent recommendations.

• Antihepatotoxic rat study (aqueous decoction, D. adscendens): A significant decrease in AST and ALT was observed for the D. adscendens decoction at a dose equivalent to 5 mg/kg/day and 20 mg/kg/day D-pinitol, as well as 20 mg/kg/day pure D-pinitol.
• Human viral hepatitis clinical report: In a clinical study on 50 patients with viral hepatitis, patients received treatment with Desmodium 3 times per day for 45 days. (Further dose-quantification details were not available in identified sources.)
• Oncology feasibility study (Desmovit® device, D. adscendens): Twelve patients received a medical device containing 300 mg of DA leaves and 50 mg of L. calcareum.
• Subchronic toxicity study (NOAEL, aqueous extract, rats): The no-observed-adverse-effect level (NOAEL) for the aqueous extract was 4000 mg/kg/day in both genders.
• Acute toxicity (LD50, oral, rats): Oral administration of leaf extract of D. adscendens to white Wistar rats in acute toxicity studies allowed the estimation of an LD50 value of 1122 mg/kg body weight.
• In vitro cytoprotection (hydroalcoholic extract, cell lines): Pretreatment with 1 mg/mL or 10 mg/mL DA did not alter viability or LDH release in HepG2 or LLC-PK1 cells.

8. Safety Considerations and Drug Interactions

8.1 Overall Toxicological Profile

The formally published toxicology data on D. adscendens is limited primarily to animal experiments. Oral administration of leaf extract of D. adscendens to white Wistar rats in acute toxicity studies allowed the estimation of an LD50 value of 1122 mg/kg body weight. During a subchronic oral toxicity study, no mortality, obvious treatment-related clinical signs, or abnormal urinalysis parameters were observed. Differences in weight gain, food consumption, haematology, biochemistry, relative organ weight, and histopathology examinations between the treated group and control group were not considered treatment-related. The no-observed-adverse-effect level (NOAEL) was 4000 mg/kg/day in both genders. Overall, these results are consistent with the plant extract being safe at the doses administered in humans.

8.2 Potential Drug Interactions — Cytochrome P450 Enzyme Induction

In subchronic toxicity studies, the plant extract caused a decrease in zoxazolamine paralysis time and prevented thiopentone from causing sleep in test animals compared to controls. The induction of CYP enzymes is an indication of a possible drug interaction when the plant extract is co-administered with other drugs. This finding is pharmacologically significant: induction of cytochrome P450 xenobiotic-metabolising enzymes could theoretically reduce the plasma concentrations and therapeutic effects of co-administered drugs that are substrates of these enzymes. This has been documented in a preclinical study; no human pharmacokinetic interaction data have been identified.

8.3 In Vitro Cell Safety

A study evaluated the safety and protective effect of a hydroalcoholic extract of D. adscendens on liver (HepG2) and kidney (LLC-PK1) cells. Pretreatment with 1 mg/mL or 10 mg/mL DA did not alter viability or LDH release in HepG2 or LLC-PK1 cells. This suggests that at concentrations tested, the extract did not exert cytotoxic effects on hepatocytes or renal tubular cells.

8.4 Limitations in the Safety Evidence Base

Extracts of D. adscendens are used for the treatment of various diseases but limited toxicological evaluations have been done on the medicinal plant. No systematic long-term human safety studies, no randomised trials specifically assessing adverse effects, and no pharmacovigilance data from large populations have been identified in the peer-reviewed literature. The safety of use in pregnancy, lactation, paediatric populations, or in individuals with severe renal or hepatic impairment has not been formally characterised in identified studies.

8.5 Standardisation Challenges

The many effects of the African medicinal herb D. adscendens were studied in the 1980s and 1990s. In spite of this, a comprehensive analytical protocol for the quality control of its constituents (soyasaponins, alkaloids, and flavonoids) has not yet been formulated and reported. The flavonoid and triterpenoid soyasaponin content of the aerial parts of D. adscendens from four geographical origins (Ghana, Nigeria, Sierra Leone, and Togo) has been studied by planar chromatography. Comparative study revealed the presence of flavonoids such as vitexin and isovitexin, and soyasaponins such as soyasaponin I. Variability in phytochemical content across geographical origins underscores the importance of source authentication for commercial preparations.

9. Overall Assessment of the Evidence Base

In vitro and in vivo works based on crude extracts, fractions, or isolated components of D. adscendens have been shown to provide scientific evidence for their conventional uses. However, the overall body of clinical (human) evidence remains sparse. The species with the highest number of studies in the genus are D. gangeticum, D. adscendens, and D. styracifolium. Several traditional medicinal uses have been experimentally supported, demonstrating the pharmacological potential of this genus. Despite the depth of preclinical research — particularly for hepatoprotection and the respiratory anti-anaphylactic/antiasthmatic mechanism — adequately powered, well-designed, controlled human clinical trials are lacking for virtually all therapeutic applications. The existing clinical evidence consists of a small (50-patient) observational report in hepatitis and a 12-patient uncontrolled feasibility study in oncology support, neither of which provide sufficient power or control to confirm efficacy.

References

• Rastogi S, Pandey MM, Rawat AK. An ethnomedicinal, phytochemical and pharmacological profile of Desmodium gangeticum (L.) DC. and Desmodium adscendens (Sw.) DC. J Ethnopharmacol. 2011;136(2):283–296. PubMed PMID: 21530632
• Manzione MG, et al. Desmodium adscendens (Sw.) DC.: A magnificent plant with biological and pharmacological properties. Food Frontiers. 2022. Wiley Online Library.
• Rastogi S et al. An ethnomedicinal, phytochemical and pharmacological profile of Desmodium gangeticum (L.) DC. and Desmodium adscendens (Sw.) DC. Journal of Ethnopharmacology. ScienceDirect.
• Magielse J, et al. Antihepatotoxic activity of a quantified Desmodium adscendens decoction and D-pinitol against chemically-induced liver damage in rats. J Ethnopharmacol. 2013. PubMed PMID: 23291573
• Quaye O, et al. Acute and Subchronic Toxicity Studies of Aqueous Extract of Desmodium adscendens (Sw) DC. J Evid Based Complementary Altern Med. 2017. PMC5871315
• Safety of Desmodium adscendens extract on hepatocytes and renal cells. Protective effect against oxidative stress. PMC4566765
• Imperatori L, et al. Feasibility single-arm study of a medical device containing Desmodium adscendens and Lithothamnium calcareum combined with chemotherapy in head and neck cancer patients. Cancer Manag Res. 2018;10:5433–5438. PMC6234998
• Addy ME. Some secondary plant metabolites in Desmodium adscendens and their effects on arachidonic acid metabolism. Phytother Res. 1992. ScienceDirect.
• Addy ME, Burka JF. Effect of Desmodium adscendens fraction 3 on contractions of respiratory smooth muscle. J Ethnopharmacol. 1990. ScienceDirect.
• Addy ME, Awumey EM. Effects of the extracts of Desmodium adscendens on anaphylaxis. J Ethnopharmacol. 1984;11(3):283–292. PubMed PMID: 6482479
• Addy ME. Several Chromatographically Distinct Fractions of Desmodium adscendens Inhibit Smooth Muscle Contractions. Int J Crude Drug Research. 1989;27(2). Taylor & Francis.
• Magielse J et al. Antihepatotoxic activity of a quantified Desmodium adscendens decoction and D-pinitol against chemically-induced liver damage in rats. J Ethnopharmacol. 2013. ScienceDirect.
• Analysis of Phytoconstituents of Desmodium Adscendens in Relation to its Therapeutic Properties. BioMed Grid.
• Phytochemical and Pharmacological Profile of Desmodium gangeticum (L.) DC.: A Comprehensive Review. Bentham Science / EurekaSelect.
• Pharmaco-chemical profiling of Desmodium gangeticum (L.) DC. with special reference to soil chemistry. PMC8520758
• Manzione MG et al. Desmodium adscendens (Sw.) DC.: A magnificent plant with biological and pharmacological properties. University of Milan repository (PDF).